Stock Detail
Videos
PolyPid (PYPD) Company Webcast
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care,...
PolyPid (PYPD) Company Webcast
PolyPid Ltd. (NASDAQ: PYPD) is a late-stage biopharmaceutical company developing innovative therapies designed to improve surgical outcomes and reduce post-operative complications. The company's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology enables...
PolyPid (PYPD) Company Webcast
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. This company webcast was recorded during the Lytham Partners 2026 Investor Healthcare Summit.
News
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
D-PLEX NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing Expanding D-PLEX Globally: MAA Submitted and Validated by the EMA and European Commercialization Rights to D-PLEX Regained "PolyPid 2030" Growth...
PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
PETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today...
PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
Company to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX November 28, 2026 PDUFA goal date PolyPid introduces PD01B, a new product candidate...



